Event Brief
Novo Nordisk Stock Drops 15% After Drug Trial Failure
Filed: Feb 23, 2026 at 6:02 AM ET
Summary: Novo Nordisk's weight loss drug CagriSema fails to meet trial goals, causing a 15% stock drop.
WHO: Novo Nordisk
WHAT: Stock drop after drug trial failure
WHEN: Feb 22, 2026 at 7:00 PM ET
WHERE: Copenhagen
WHY: Drug did not meet primary target in trial
ℹ️ This event is analyzed using pattern arcs, velocity indicators, and source analysis in our MI Console.
Know more. Read less.
The BriefBrief follows the story, so you don't have to read every article. See what happened, how it changed, and where it came from, all in one place.
Same format. Every time.
See how stories unfold →